Global Anti-diabetic Medication Market

Anti-diabetic Medication Comprehensive Study by Type (Insulin (Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin), Drug class (Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione)), Application (Prevent and Treatment Diabetes, Obesity Treatment, Cardiovascular Protection, Others), Route of Administration (Insulin Syringe/ Insulin Pen, Insulin Pump, Intravenous Infusion, Oral, Others), End User (Pediatric, Adult, Geriatric) Players and Region - Global Market Outlook to 2028

Anti-diabetic Medication Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Anti-diabetic Medication Market?

Anti-diabetic medications are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Anti-diabetic medications are commonly used to manage diabetes. Anti-diabetic medications are all pharmacological agents that have been approved for hyperglycemic treatment in diabetes mellitus. The increasing prevalence of diabetes across the globe will stimulate the market potential for anti-diabetic medication during the forecast period.

Highlights from Anti-diabetic Medication Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAstraZeneca plc (United Kingdom), Bayer AG (Germany), C.H. Boehringer Sohn AG & Ko. KG (Germany), Bristol-Myers Squibb (United States), Eli Lilly (United States), Halozyme Therapeutics (United States), Johnson & Johnson (United States), Merck & Co. Inc. (United States), Novartis AG (Switzerland) and Pfizer Inc. (United States)


Anti-diabetic medication market is a fragmented market due to the presence of various players. The players are focusing on increasing their manufacturing capacity. Further, companies are focusing on developing innovative products and solutions to improve quality, enhances and promotes performance. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launch, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Anti-diabetic Medication market throughout the forecasted period.

AstraZeneca plc (United Kingdom), Bayer AG (Germany), C.H. Boehringer Sohn AG & Ko. KG (Germany), Bristol-Myers Squibb (United States), Eli Lilly (United States), Halozyme Therapeutics (United States), Johnson & Johnson (United States), Merck & Co. Inc. (United States), Novartis AG (Switzerland) and Pfizer Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Novo Nordisk (Denmark), Oramed Pharmaceuticals Inc. (Israel), Sanofi (France) and Takeda Pharmaceutical (Japan).

Anti-diabetic Medication Market Segmentation:
ScopeSub-Segments
Application / End UserPrevent and Treatment Diabetes, Obesity Treatment, Cardiovascular Protection and Others
TypeInsulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin] and Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione]
Route of AdministrationInsulin Syringe/ Insulin Pen,Insulin Pump,Intravenous Infusion,Oral,Others
End UserPediatric,Adult,Geriatric


On the basis of geography, the market of Anti-diabetic Medication has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Adoption of Oral Antidiabetic Drugs

Market Growth Drivers:
Rising Prevalence of Chronic Diseases like Diabetes across the Globe and Growing Prevalence of Lifestyle-Induced Disorders such as Obesity

Challenges:
Safety Issues Pertaining to Some Diabetic Drugs

Restraints:
Prohibitive Cost of Insulin

Opportunities:
Rising Spending on Research and Development for Innovative Drugs

Key Target Audience
Anti-diabetic Medication Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Market Leaders & Development Strategies
In February 2018, Cipla collaborated with Novartis and Johnson & Johnson to market their anti-diabetic drugs. This collaboration has led to the business expansion of the firm thereby strengthening its market position.
In December 2019, Mankind Pharmaceuticals signed a collaborative marketing agreement with Glenmark Pharmaceuticals to market remoglifozin, an antidiabetic drug, in India. This has allowed both firms to expand their business in the Asia Pacific region.


Report Objectives / Segmentation Covered

By Type
  • Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin]
  • Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione]
By Application
  • Prevent and Treatment Diabetes
  • Obesity Treatment
  • Cardiovascular Protection
  • Others
By Route of Administration
  • Insulin Syringe/ Insulin Pen
  • Insulin Pump
  • Intravenous Infusion
  • Oral
  • Others

By End User
  • Pediatric
  • Adult
  • Geriatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Chronic Diseases like Diabetes across the Globe
      • 3.2.2. Growing Prevalence of Lifestyle-Induced Disorders such as Obesity
    • 3.3. Market Challenges
      • 3.3.1. Safety Issues Pertaining to Some Diabetic Drugs
    • 3.4. Market Trends
      • 3.4.1. Increasing Adoption of Oral Antidiabetic Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti-diabetic Medication, by Type, Application, Route of Administration, End User and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Anti-diabetic Medication (Value)
      • 5.2.1. Global Anti-diabetic Medication by: Type (Value)
        • 5.2.1.1. Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin]
        • 5.2.1.2. Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione]
      • 5.2.2. Global Anti-diabetic Medication by: Application (Value)
        • 5.2.2.1. Prevent and Treatment Diabetes
        • 5.2.2.2. Obesity Treatment
        • 5.2.2.3. Cardiovascular Protection
        • 5.2.2.4. Others
      • 5.2.3. Global Anti-diabetic Medication by: Route of Administration (Value)
        • 5.2.3.1. Insulin Syringe/ Insulin Pen
        • 5.2.3.2. Insulin Pump
        • 5.2.3.3. Intravenous Infusion
        • 5.2.3.4. Oral
        • 5.2.3.5. Others
      • 5.2.4. Global Anti-diabetic Medication by: End User (Value)
        • 5.2.4.1. Pediatric
        • 5.2.4.2. Adult
        • 5.2.4.3. Geriatric
      • 5.2.5. Global Anti-diabetic Medication Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Anti-diabetic Medication (Volume)
      • 5.3.1. Global Anti-diabetic Medication by: Type (Volume)
        • 5.3.1.1. Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin]
        • 5.3.1.2. Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione]
      • 5.3.2. Global Anti-diabetic Medication by: Application (Volume)
        • 5.3.2.1. Prevent and Treatment Diabetes
        • 5.3.2.2. Obesity Treatment
        • 5.3.2.3. Cardiovascular Protection
        • 5.3.2.4. Others
      • 5.3.3. Global Anti-diabetic Medication by: Route of Administration (Volume)
        • 5.3.3.1. Insulin Syringe/ Insulin Pen
        • 5.3.3.2. Insulin Pump
        • 5.3.3.3. Intravenous Infusion
        • 5.3.3.4. Oral
        • 5.3.3.5. Others
      • 5.3.4. Global Anti-diabetic Medication by: End User (Volume)
        • 5.3.4.1. Pediatric
        • 5.3.4.2. Adult
        • 5.3.4.3. Geriatric
      • 5.3.5. Global Anti-diabetic Medication Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Anti-diabetic Medication (Price)
      • 5.4.1. Global Anti-diabetic Medication by: Type (Price)
  • 6. Anti-diabetic Medication: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. C.H. Boehringer Sohn AG & Ko. KG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol-Myers Squibb (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Halozyme Therapeutics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co. Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Anti-diabetic Medication Sale, by Type, Application, Route of Administration, End User and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Anti-diabetic Medication (Value)
      • 7.2.1. Global Anti-diabetic Medication by: Type (Value)
        • 7.2.1.1. Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin]
        • 7.2.1.2. Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione]
      • 7.2.2. Global Anti-diabetic Medication by: Application (Value)
        • 7.2.2.1. Prevent and Treatment Diabetes
        • 7.2.2.2. Obesity Treatment
        • 7.2.2.3. Cardiovascular Protection
        • 7.2.2.4. Others
      • 7.2.3. Global Anti-diabetic Medication by: Route of Administration (Value)
        • 7.2.3.1. Insulin Syringe/ Insulin Pen
        • 7.2.3.2. Insulin Pump
        • 7.2.3.3. Intravenous Infusion
        • 7.2.3.4. Oral
        • 7.2.3.5. Others
      • 7.2.4. Global Anti-diabetic Medication by: End User (Value)
        • 7.2.4.1. Pediatric
        • 7.2.4.2. Adult
        • 7.2.4.3. Geriatric
      • 7.2.5. Global Anti-diabetic Medication Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Anti-diabetic Medication (Volume)
      • 7.3.1. Global Anti-diabetic Medication by: Type (Volume)
        • 7.3.1.1. Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin]
        • 7.3.1.2. Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione]
      • 7.3.2. Global Anti-diabetic Medication by: Application (Volume)
        • 7.3.2.1. Prevent and Treatment Diabetes
        • 7.3.2.2. Obesity Treatment
        • 7.3.2.3. Cardiovascular Protection
        • 7.3.2.4. Others
      • 7.3.3. Global Anti-diabetic Medication by: Route of Administration (Volume)
        • 7.3.3.1. Insulin Syringe/ Insulin Pen
        • 7.3.3.2. Insulin Pump
        • 7.3.3.3. Intravenous Infusion
        • 7.3.3.4. Oral
        • 7.3.3.5. Others
      • 7.3.4. Global Anti-diabetic Medication by: End User (Volume)
        • 7.3.4.1. Pediatric
        • 7.3.4.2. Adult
        • 7.3.4.3. Geriatric
      • 7.3.5. Global Anti-diabetic Medication Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Anti-diabetic Medication (Price)
      • 7.4.1. Global Anti-diabetic Medication by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti-diabetic Medication: by Type(USD Million)
  • Table 2. Anti-diabetic Medication Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin] , by Region USD Million (2017-2022)
  • Table 3. Anti-diabetic Medication Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione] , by Region USD Million (2017-2022)
  • Table 4. Anti-diabetic Medication: by Application(USD Million)
  • Table 5. Anti-diabetic Medication Prevent and Treatment Diabetes , by Region USD Million (2017-2022)
  • Table 6. Anti-diabetic Medication Obesity Treatment , by Region USD Million (2017-2022)
  • Table 7. Anti-diabetic Medication Cardiovascular Protection , by Region USD Million (2017-2022)
  • Table 8. Anti-diabetic Medication Others , by Region USD Million (2017-2022)
  • Table 9. Anti-diabetic Medication: by Route of Administration(USD Million)
  • Table 10. Anti-diabetic Medication Insulin Syringe/ Insulin Pen , by Region USD Million (2017-2022)
  • Table 11. Anti-diabetic Medication Insulin Pump , by Region USD Million (2017-2022)
  • Table 12. Anti-diabetic Medication Intravenous Infusion , by Region USD Million (2017-2022)
  • Table 13. Anti-diabetic Medication Oral , by Region USD Million (2017-2022)
  • Table 14. Anti-diabetic Medication Others , by Region USD Million (2017-2022)
  • Table 15. Anti-diabetic Medication: by End User(USD Million)
  • Table 16. Anti-diabetic Medication Pediatric , by Region USD Million (2017-2022)
  • Table 17. Anti-diabetic Medication Adult , by Region USD Million (2017-2022)
  • Table 18. Anti-diabetic Medication Geriatric , by Region USD Million (2017-2022)
  • Table 19. South America Anti-diabetic Medication, by Country USD Million (2017-2022)
  • Table 20. South America Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 21. South America Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 22. South America Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 23. South America Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 24. Brazil Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 25. Brazil Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 26. Brazil Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 27. Brazil Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 28. Argentina Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 29. Argentina Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 30. Argentina Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 31. Argentina Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 32. Rest of South America Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 33. Rest of South America Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 34. Rest of South America Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 35. Rest of South America Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 36. Asia Pacific Anti-diabetic Medication, by Country USD Million (2017-2022)
  • Table 37. Asia Pacific Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 38. Asia Pacific Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 39. Asia Pacific Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 40. Asia Pacific Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 41. China Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 42. China Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 43. China Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 44. China Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 45. Japan Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 46. Japan Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 47. Japan Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 48. Japan Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 49. India Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 50. India Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 51. India Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 52. India Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 53. South Korea Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 54. South Korea Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 55. South Korea Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 56. South Korea Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 57. Taiwan Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 58. Taiwan Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 59. Taiwan Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 60. Taiwan Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 61. Australia Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 62. Australia Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 63. Australia Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 64. Australia Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 69. Europe Anti-diabetic Medication, by Country USD Million (2017-2022)
  • Table 70. Europe Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 71. Europe Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 72. Europe Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 73. Europe Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 74. Germany Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 75. Germany Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 76. Germany Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 77. Germany Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 78. France Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 79. France Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 80. France Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 81. France Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 82. Italy Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 83. Italy Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 84. Italy Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 85. Italy Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 86. United Kingdom Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 87. United Kingdom Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 88. United Kingdom Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 89. United Kingdom Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 90. Netherlands Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 91. Netherlands Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 92. Netherlands Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 93. Netherlands Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 94. Rest of Europe Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 95. Rest of Europe Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 96. Rest of Europe Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 97. Rest of Europe Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 98. MEA Anti-diabetic Medication, by Country USD Million (2017-2022)
  • Table 99. MEA Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 100. MEA Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 101. MEA Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 102. MEA Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 103. Middle East Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 104. Middle East Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 105. Middle East Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 106. Middle East Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 107. Africa Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 108. Africa Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 109. Africa Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 110. Africa Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 111. North America Anti-diabetic Medication, by Country USD Million (2017-2022)
  • Table 112. North America Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 113. North America Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 114. North America Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 115. North America Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 116. United States Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 117. United States Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 118. United States Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 119. United States Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 120. Canada Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 121. Canada Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 122. Canada Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 123. Canada Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 124. Mexico Anti-diabetic Medication, by Type USD Million (2017-2022)
  • Table 125. Mexico Anti-diabetic Medication, by Application USD Million (2017-2022)
  • Table 126. Mexico Anti-diabetic Medication, by Route of Administration USD Million (2017-2022)
  • Table 127. Mexico Anti-diabetic Medication, by End User USD Million (2017-2022)
  • Table 128. Anti-diabetic Medication Sales: by Type(KG)
  • Table 129. Anti-diabetic Medication Sales Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin] , by Region KG (2017-2022)
  • Table 130. Anti-diabetic Medication Sales Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione] , by Region KG (2017-2022)
  • Table 131. Anti-diabetic Medication Sales: by Application(KG)
  • Table 132. Anti-diabetic Medication Sales Prevent and Treatment Diabetes , by Region KG (2017-2022)
  • Table 133. Anti-diabetic Medication Sales Obesity Treatment , by Region KG (2017-2022)
  • Table 134. Anti-diabetic Medication Sales Cardiovascular Protection , by Region KG (2017-2022)
  • Table 135. Anti-diabetic Medication Sales Others , by Region KG (2017-2022)
  • Table 136. Anti-diabetic Medication Sales: by Route of Administration(KG)
  • Table 137. Anti-diabetic Medication Sales Insulin Syringe/ Insulin Pen , by Region KG (2017-2022)
  • Table 138. Anti-diabetic Medication Sales Insulin Pump , by Region KG (2017-2022)
  • Table 139. Anti-diabetic Medication Sales Intravenous Infusion , by Region KG (2017-2022)
  • Table 140. Anti-diabetic Medication Sales Oral , by Region KG (2017-2022)
  • Table 141. Anti-diabetic Medication Sales Others , by Region KG (2017-2022)
  • Table 142. Anti-diabetic Medication Sales: by End User(KG)
  • Table 143. Anti-diabetic Medication Sales Pediatric , by Region KG (2017-2022)
  • Table 144. Anti-diabetic Medication Sales Adult , by Region KG (2017-2022)
  • Table 145. Anti-diabetic Medication Sales Geriatric , by Region KG (2017-2022)
  • Table 146. South America Anti-diabetic Medication Sales, by Country KG (2017-2022)
  • Table 147. South America Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 148. South America Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 149. South America Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 150. South America Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 151. Brazil Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 152. Brazil Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 153. Brazil Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 154. Brazil Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 155. Argentina Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 156. Argentina Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 157. Argentina Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 158. Argentina Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 159. Rest of South America Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 160. Rest of South America Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 161. Rest of South America Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 162. Rest of South America Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 163. Asia Pacific Anti-diabetic Medication Sales, by Country KG (2017-2022)
  • Table 164. Asia Pacific Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 165. Asia Pacific Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 166. Asia Pacific Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 167. Asia Pacific Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 168. China Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 169. China Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 170. China Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 171. China Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 172. Japan Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 173. Japan Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 174. Japan Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 175. Japan Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 176. India Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 177. India Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 178. India Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 179. India Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 180. South Korea Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 181. South Korea Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 182. South Korea Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 183. South Korea Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 184. Taiwan Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 185. Taiwan Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 186. Taiwan Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 187. Taiwan Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 188. Australia Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 189. Australia Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 190. Australia Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 191. Australia Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 192. Rest of Asia-Pacific Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 193. Rest of Asia-Pacific Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 194. Rest of Asia-Pacific Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 195. Rest of Asia-Pacific Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 196. Europe Anti-diabetic Medication Sales, by Country KG (2017-2022)
  • Table 197. Europe Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 198. Europe Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 199. Europe Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 200. Europe Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 201. Germany Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 202. Germany Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 203. Germany Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 204. Germany Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 205. France Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 206. France Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 207. France Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 208. France Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 209. Italy Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 210. Italy Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 211. Italy Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 212. Italy Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 213. United Kingdom Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 214. United Kingdom Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 215. United Kingdom Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 216. United Kingdom Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 217. Netherlands Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 218. Netherlands Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 219. Netherlands Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 220. Netherlands Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 221. Rest of Europe Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 222. Rest of Europe Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 223. Rest of Europe Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 224. Rest of Europe Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 225. MEA Anti-diabetic Medication Sales, by Country KG (2017-2022)
  • Table 226. MEA Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 227. MEA Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 228. MEA Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 229. MEA Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 230. Middle East Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 231. Middle East Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 232. Middle East Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 233. Middle East Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 234. Africa Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 235. Africa Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 236. Africa Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 237. Africa Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 238. North America Anti-diabetic Medication Sales, by Country KG (2017-2022)
  • Table 239. North America Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 240. North America Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 241. North America Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 242. North America Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 243. United States Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 244. United States Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 245. United States Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 246. United States Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 247. Canada Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 248. Canada Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 249. Canada Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 250. Canada Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 251. Mexico Anti-diabetic Medication Sales, by Type KG (2017-2022)
  • Table 252. Mexico Anti-diabetic Medication Sales, by Application KG (2017-2022)
  • Table 253. Mexico Anti-diabetic Medication Sales, by Route of Administration KG (2017-2022)
  • Table 254. Mexico Anti-diabetic Medication Sales, by End User KG (2017-2022)
  • Table 255. Anti-diabetic Medication: by Type(USD/Units)
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Anti-diabetic Medication: by Type(USD Million)
  • Table 267. Anti-diabetic Medication Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin] , by Region USD Million (2023-2028)
  • Table 268. Anti-diabetic Medication Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione] , by Region USD Million (2023-2028)
  • Table 269. Anti-diabetic Medication: by Application(USD Million)
  • Table 270. Anti-diabetic Medication Prevent and Treatment Diabetes , by Region USD Million (2023-2028)
  • Table 271. Anti-diabetic Medication Obesity Treatment , by Region USD Million (2023-2028)
  • Table 272. Anti-diabetic Medication Cardiovascular Protection , by Region USD Million (2023-2028)
  • Table 273. Anti-diabetic Medication Others , by Region USD Million (2023-2028)
  • Table 274. Anti-diabetic Medication: by Route of Administration(USD Million)
  • Table 275. Anti-diabetic Medication Insulin Syringe/ Insulin Pen , by Region USD Million (2023-2028)
  • Table 276. Anti-diabetic Medication Insulin Pump , by Region USD Million (2023-2028)
  • Table 277. Anti-diabetic Medication Intravenous Infusion , by Region USD Million (2023-2028)
  • Table 278. Anti-diabetic Medication Oral , by Region USD Million (2023-2028)
  • Table 279. Anti-diabetic Medication Others , by Region USD Million (2023-2028)
  • Table 280. Anti-diabetic Medication: by End User(USD Million)
  • Table 281. Anti-diabetic Medication Pediatric , by Region USD Million (2023-2028)
  • Table 282. Anti-diabetic Medication Adult , by Region USD Million (2023-2028)
  • Table 283. Anti-diabetic Medication Geriatric , by Region USD Million (2023-2028)
  • Table 284. South America Anti-diabetic Medication, by Country USD Million (2023-2028)
  • Table 285. South America Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 286. South America Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 287. South America Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 288. South America Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 289. Brazil Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 290. Brazil Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 291. Brazil Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 292. Brazil Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 293. Argentina Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 294. Argentina Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 295. Argentina Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 296. Argentina Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 297. Rest of South America Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 298. Rest of South America Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 299. Rest of South America Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 300. Rest of South America Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 301. Asia Pacific Anti-diabetic Medication, by Country USD Million (2023-2028)
  • Table 302. Asia Pacific Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 303. Asia Pacific Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 304. Asia Pacific Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 305. Asia Pacific Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 306. China Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 307. China Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 308. China Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 309. China Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 310. Japan Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 311. Japan Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 312. Japan Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 313. Japan Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 314. India Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 315. India Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 316. India Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 317. India Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 318. South Korea Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 319. South Korea Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 320. South Korea Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 321. South Korea Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 322. Taiwan Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 323. Taiwan Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 324. Taiwan Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 325. Taiwan Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 326. Australia Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 327. Australia Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 328. Australia Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 329. Australia Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 330. Rest of Asia-Pacific Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 331. Rest of Asia-Pacific Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 332. Rest of Asia-Pacific Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 333. Rest of Asia-Pacific Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 334. Europe Anti-diabetic Medication, by Country USD Million (2023-2028)
  • Table 335. Europe Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 336. Europe Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 337. Europe Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 338. Europe Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 339. Germany Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 340. Germany Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 341. Germany Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 342. Germany Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 343. France Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 344. France Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 345. France Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 346. France Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 347. Italy Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 348. Italy Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 349. Italy Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 350. Italy Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 351. United Kingdom Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 352. United Kingdom Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 353. United Kingdom Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 354. United Kingdom Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 355. Netherlands Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 356. Netherlands Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 357. Netherlands Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 358. Netherlands Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 359. Rest of Europe Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 360. Rest of Europe Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 361. Rest of Europe Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 362. Rest of Europe Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 363. MEA Anti-diabetic Medication, by Country USD Million (2023-2028)
  • Table 364. MEA Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 365. MEA Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 366. MEA Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 367. MEA Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 368. Middle East Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 369. Middle East Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 370. Middle East Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 371. Middle East Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 372. Africa Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 373. Africa Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 374. Africa Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 375. Africa Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 376. North America Anti-diabetic Medication, by Country USD Million (2023-2028)
  • Table 377. North America Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 378. North America Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 379. North America Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 380. North America Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 381. United States Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 382. United States Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 383. United States Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 384. United States Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 385. Canada Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 386. Canada Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 387. Canada Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 388. Canada Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 389. Mexico Anti-diabetic Medication, by Type USD Million (2023-2028)
  • Table 390. Mexico Anti-diabetic Medication, by Application USD Million (2023-2028)
  • Table 391. Mexico Anti-diabetic Medication, by Route of Administration USD Million (2023-2028)
  • Table 392. Mexico Anti-diabetic Medication, by End User USD Million (2023-2028)
  • Table 393. Anti-diabetic Medication Sales: by Type(KG)
  • Table 394. Anti-diabetic Medication Sales Insulin [Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin] , by Region KG (2023-2028)
  • Table 395. Anti-diabetic Medication Sales Drug class [Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione] , by Region KG (2023-2028)
  • Table 396. Anti-diabetic Medication Sales: by Application(KG)
  • Table 397. Anti-diabetic Medication Sales Prevent and Treatment Diabetes , by Region KG (2023-2028)
  • Table 398. Anti-diabetic Medication Sales Obesity Treatment , by Region KG (2023-2028)
  • Table 399. Anti-diabetic Medication Sales Cardiovascular Protection , by Region KG (2023-2028)
  • Table 400. Anti-diabetic Medication Sales Others , by Region KG (2023-2028)
  • Table 401. Anti-diabetic Medication Sales: by Route of Administration(KG)
  • Table 402. Anti-diabetic Medication Sales Insulin Syringe/ Insulin Pen , by Region KG (2023-2028)
  • Table 403. Anti-diabetic Medication Sales Insulin Pump , by Region KG (2023-2028)
  • Table 404. Anti-diabetic Medication Sales Intravenous Infusion , by Region KG (2023-2028)
  • Table 405. Anti-diabetic Medication Sales Oral , by Region KG (2023-2028)
  • Table 406. Anti-diabetic Medication Sales Others , by Region KG (2023-2028)
  • Table 407. Anti-diabetic Medication Sales: by End User(KG)
  • Table 408. Anti-diabetic Medication Sales Pediatric , by Region KG (2023-2028)
  • Table 409. Anti-diabetic Medication Sales Adult , by Region KG (2023-2028)
  • Table 410. Anti-diabetic Medication Sales Geriatric , by Region KG (2023-2028)
  • Table 411. South America Anti-diabetic Medication Sales, by Country KG (2023-2028)
  • Table 412. South America Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 413. South America Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 414. South America Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 415. South America Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 416. Brazil Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 417. Brazil Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 418. Brazil Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 419. Brazil Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 420. Argentina Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 421. Argentina Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 422. Argentina Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 423. Argentina Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 424. Rest of South America Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 425. Rest of South America Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 426. Rest of South America Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 427. Rest of South America Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 428. Asia Pacific Anti-diabetic Medication Sales, by Country KG (2023-2028)
  • Table 429. Asia Pacific Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 430. Asia Pacific Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 431. Asia Pacific Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 432. Asia Pacific Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 433. China Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 434. China Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 435. China Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 436. China Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 437. Japan Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 438. Japan Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 439. Japan Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 440. Japan Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 441. India Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 442. India Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 443. India Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 444. India Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 445. South Korea Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 446. South Korea Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 447. South Korea Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 448. South Korea Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 449. Taiwan Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 450. Taiwan Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 451. Taiwan Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 452. Taiwan Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 453. Australia Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 454. Australia Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 455. Australia Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 456. Australia Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 457. Rest of Asia-Pacific Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 458. Rest of Asia-Pacific Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 459. Rest of Asia-Pacific Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 460. Rest of Asia-Pacific Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 461. Europe Anti-diabetic Medication Sales, by Country KG (2023-2028)
  • Table 462. Europe Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 463. Europe Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 464. Europe Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 465. Europe Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 466. Germany Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 467. Germany Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 468. Germany Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 469. Germany Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 470. France Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 471. France Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 472. France Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 473. France Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 474. Italy Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 475. Italy Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 476. Italy Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 477. Italy Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 478. United Kingdom Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 479. United Kingdom Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 480. United Kingdom Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 481. United Kingdom Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 482. Netherlands Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 483. Netherlands Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 484. Netherlands Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 485. Netherlands Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 486. Rest of Europe Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 487. Rest of Europe Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 488. Rest of Europe Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 489. Rest of Europe Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 490. MEA Anti-diabetic Medication Sales, by Country KG (2023-2028)
  • Table 491. MEA Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 492. MEA Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 493. MEA Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 494. MEA Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 495. Middle East Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 496. Middle East Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 497. Middle East Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 498. Middle East Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 499. Africa Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 500. Africa Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 501. Africa Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 502. Africa Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 503. North America Anti-diabetic Medication Sales, by Country KG (2023-2028)
  • Table 504. North America Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 505. North America Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 506. North America Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 507. North America Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 508. United States Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 509. United States Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 510. United States Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 511. United States Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 512. Canada Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 513. Canada Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 514. Canada Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 515. Canada Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 516. Mexico Anti-diabetic Medication Sales, by Type KG (2023-2028)
  • Table 517. Mexico Anti-diabetic Medication Sales, by Application KG (2023-2028)
  • Table 518. Mexico Anti-diabetic Medication Sales, by Route of Administration KG (2023-2028)
  • Table 519. Mexico Anti-diabetic Medication Sales, by End User KG (2023-2028)
  • Table 520. Anti-diabetic Medication: by Type(USD/Units)
  • Table 521. Research Programs/Design for This Report
  • Table 522. Key Data Information from Secondary Sources
  • Table 523. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti-diabetic Medication: by Type USD Million (2017-2022)
  • Figure 5. Global Anti-diabetic Medication: by Application USD Million (2017-2022)
  • Figure 6. Global Anti-diabetic Medication: by Route of Administration USD Million (2017-2022)
  • Figure 7. Global Anti-diabetic Medication: by End User USD Million (2017-2022)
  • Figure 8. South America Anti-diabetic Medication Share (%), by Country
  • Figure 9. Asia Pacific Anti-diabetic Medication Share (%), by Country
  • Figure 10. Europe Anti-diabetic Medication Share (%), by Country
  • Figure 11. MEA Anti-diabetic Medication Share (%), by Country
  • Figure 12. North America Anti-diabetic Medication Share (%), by Country
  • Figure 13. Global Anti-diabetic Medication: by Type KG (2017-2022)
  • Figure 14. Global Anti-diabetic Medication: by Application KG (2017-2022)
  • Figure 15. Global Anti-diabetic Medication: by Route of Administration KG (2017-2022)
  • Figure 16. Global Anti-diabetic Medication: by End User KG (2017-2022)
  • Figure 17. South America Anti-diabetic Medication Share (%), by Country
  • Figure 18. Asia Pacific Anti-diabetic Medication Share (%), by Country
  • Figure 19. Europe Anti-diabetic Medication Share (%), by Country
  • Figure 20. MEA Anti-diabetic Medication Share (%), by Country
  • Figure 21. North America Anti-diabetic Medication Share (%), by Country
  • Figure 22. Global Anti-diabetic Medication: by Type USD/Units (2017-2022)
  • Figure 23. Global Anti-diabetic Medication share by Players 2022 (%)
  • Figure 24. Global Anti-diabetic Medication share by Players (Top 3) 2022(%)
  • Figure 25. Global Anti-diabetic Medication share by Players (Top 5) 2022(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. AstraZeneca plc (United Kingdom) Revenue: by Geography 2022
  • Figure 29. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 31. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 32. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue: by Geography 2022
  • Figure 33. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 34. Bristol-Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 35. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 36. Eli Lilly (United States) Revenue: by Geography 2022
  • Figure 37. Halozyme Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 38. Halozyme Therapeutics (United States) Revenue: by Geography 2022
  • Figure 39. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 40. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 41. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Merck & Co. Inc. (United States) Revenue: by Geography 2022
  • Figure 43. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 45. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 47. Global Anti-diabetic Medication: by Type USD Million (2023-2028)
  • Figure 48. Global Anti-diabetic Medication: by Application USD Million (2023-2028)
  • Figure 49. Global Anti-diabetic Medication: by Route of Administration USD Million (2023-2028)
  • Figure 50. Global Anti-diabetic Medication: by End User USD Million (2023-2028)
  • Figure 51. South America Anti-diabetic Medication Share (%), by Country
  • Figure 52. Asia Pacific Anti-diabetic Medication Share (%), by Country
  • Figure 53. Europe Anti-diabetic Medication Share (%), by Country
  • Figure 54. MEA Anti-diabetic Medication Share (%), by Country
  • Figure 55. North America Anti-diabetic Medication Share (%), by Country
  • Figure 56. Global Anti-diabetic Medication: by Type KG (2023-2028)
  • Figure 57. Global Anti-diabetic Medication: by Application KG (2023-2028)
  • Figure 58. Global Anti-diabetic Medication: by Route of Administration KG (2023-2028)
  • Figure 59. Global Anti-diabetic Medication: by End User KG (2023-2028)
  • Figure 60. South America Anti-diabetic Medication Share (%), by Country
  • Figure 61. Asia Pacific Anti-diabetic Medication Share (%), by Country
  • Figure 62. Europe Anti-diabetic Medication Share (%), by Country
  • Figure 63. MEA Anti-diabetic Medication Share (%), by Country
  • Figure 64. North America Anti-diabetic Medication Share (%), by Country
  • Figure 65. Global Anti-diabetic Medication: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • AstraZeneca plc (United Kingdom)
  • Bayer AG (Germany)
  • C.H. Boehringer Sohn AG & Ko. KG (Germany)
  • Bristol-Myers Squibb (United States)
  • Eli Lilly (United States)
  • Halozyme Therapeutics (United States)
  • Johnson & Johnson (United States)
  • Merck & Co. Inc. (United States)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
Additional players considered in the study are as follows:
Novo Nordisk (Denmark) , Oramed Pharmaceuticals Inc. (Israel) , Sanofi (France) , Takeda Pharmaceutical (Japan)
Select User Access Type

Key Highlights of Report


May 2023 249 Pages 60 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anti-diabetic Medication Market Quantitative research analysis
Global Anti-diabetic Medication Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rising Prevalence of Chronic Diseases like Diabetes across the Globe " is seen as one of major growth factors of Anti-diabetic Medication Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Anti-diabetic Medication market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Anti-diabetic Medication Market Report?

Have a Query? Click Here

Other Related Reports

Pyrazinamide Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Adult, Pediatric)
$ 3500
Vaginal Fungi Infections Treatment Comprehensive Study by Type (Fluconazole, Nystatin, Flucytosine, Others), Route of Administration (Injection, Ointment, Oral), Distribution Channel (Online, Offline...
$ 3450
Oral Antibiotics Comprehensive Study by Type (Branded, Generic), Application (Community-Respiratory Tract Infections (CARTIS) (Upper Respiratory Tract Infections (URTI), and ower Respiratory Tract In...
$ 3750
Peripheral Artery Disease Comprehensive Study by Type (Peripheral Angioplasty Balloons,, Peripheral Stents,, Peripheral Catheters,, Inferior Vena Cava (IVC), Plaque Modification Devices, Hemodynamic ...
$ 3750
Parkinson's Disease Drugs Comprehensive Study by Type (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Route of Administration (Oral, Injection, Transdermal), End-users (Hospitals, C...
$ 3450
Antitumor Antibiotics Comprehensive Study by Type (Anthracyclines (doxorubicin, daunorubicin, epirubicin, mitoxantrone, and idarubicin), Chromomycin (dactinomycin and plicamycin), Miscellaneous (mito...
$ 3650